含氮杂环氧钒配合物对PTP1B和ALP的抑制活性研究

蛋白酪氨酸磷酸酶1B (protein tyrosine phosphatase 1B, PTP1B)是当前开发治疗糖尿病药物的优秀靶标, 也是钒配合物抗糖尿病作用相关的重要靶蛋白. 研究了三种含氮平面杂环螯合配体2,2’-联咪唑(L1), 2,2’-联吡啶(L2), 1,10-邻菲咯啉(L3)的氧钒配合物对PTP1B以及碱性磷酸酶(alkaline phosphatase, ALP)的体外抑制作用. 结果表明, 1∶1和2∶1型配位的氧钒化合物均表现出对PTP1B较强的抑制活性, IC50值在120～260 nmol/L间, 抑制能力接近双麦芽酚氧钒配合物(BMOV). 抑制动力学实验表明这些氧钒配合物对PTP1B的抑制模式均为竞争性抑制, 抑制常数在20～160 nmol/L. 其对PTP1B抑制活性较ALP高103倍, 表明氧钒配合物对两种磷酸酶的抑制具有一定的选择性.     

生物小分子钒配合物抑制蛋白酪氨酸磷酸酶活性研究

钒化合物治疗糖尿病机理研究表明其与蛋白酪氨酸磷酸酶的酶活抑制有一定关系。本文分别研究了生物小分子配体与氧钒离子在20:1配比条件下形成的生物小分子钒配合物及其对蛋白酪氨酸磷酸酶的抑制作用和选择性。结果表明氨基酸与氧钒离子配合形成2:1的配合物,而抗坏血酸及多羧酸与氧钒离子配合形成1:1的配合物。它们对蛋白酪氨酸磷酸酶抑制作用显示,大部分生物小分子氧钒配合物对PTP1B表现强烈的抑制作用,IC50值在0.12~0.63μmol.L-1之间。化合物[VO(Phe)2]表现最强的抑制作用,IC50值为0.07μmol.L-1。而[VO(Arg)2]、[VO(Oxalate)]、[VO(Nitrilotriacetate)]和[VO(Citrate)]则呈现较弱的抑制,IC50值分别为1.05、1.41、9.90和21.5μmol.L-1。对PTP1B,TCPTP,HePTP以及SHP-1的抑制作用表明配体的结构不仅影响氧钒配合物对蛋白酪氨酸磷酸酶的抑制效率同时也影响其选择性。     

生物小分子钒配合物抑制蛋白酪氨酸磷酸酶活性研究

钒化合物治疗糖尿病机理研究表明其与蛋白酪氨酸磷酸酶的酶活抑制有一定关系。本文分别研究了生物小分子配体与氧钒离子在20:1配比条件下形成的生物小分子钒配合物及其对蛋白酪氨酸磷酸酶的抑制作用和选择性。结果表明氨基酸与氧钒离子配合形成2:1的配合物, 而抗坏血酸及多羧酸与氧钒离子配合形成1:1的配合物。它们对蛋白酪氨酸磷酸酶抑制作用显示, 大部分生物小分子氧钒配合物对PTP1B表现强烈的抑制作用, IC₅₀值在0.12~0.63 μmol·L^-1之间。化合物[VO(Phe)₂]表现最强的抑制作用, IC₅₀值为0.07 μmol·L^-1。而[VO(Arg)₂]、[VO(Oxalate)]、[VO(Nitrilotriacetate)]和[VO(Citrate)]则呈现较弱的抑制, IC₅₀值分别为1.05、1.41、9.90和21.5 μmol·L^-1。对PTP1B, TCPTP, HePTP以及SHP-1的抑制作用表明配体的结构不仅影响氧钒配合物对蛋白酪氨酸磷酸酶的抑制效率同时也影响其选择性。     

多苯并咪唑锌配合物抑制蛋白酪氨酸磷酸酶(PTPs)的活性

本文报道了5种多苯并咪唑锌配合物,即[Zn(TDB)_2]Cl_2(1)、[Zn(NTB)Cl]Cl(2)、[Zn(EDTB)]Cl_2(3)、[Zn_2(EGTB)Cl_2]Cl_2(4)和[Zn_2(DTPB)Cl_3]Cl(5),其中TDB=1,2-二(2-苯并咪唑)-1,2-二羟基乙烷、NTB=N,N,N-三(2-甲基苯并咪唑)胺、EDTB=N,N,N′,N′-四(2-苯并咪唑亚甲基)-1,2-乙二胺、EGTB=N,N,N′,N′-四(2-苯并咪唑甲基)-1,4-二乙胺基乙二醚以及DTPB=N,N,N′,N″,N″-五(2-苯并咪唑甲基)-二乙三胺,对5种蛋白酪氨酸磷酸酶(PTP1B、TCPTP、PTP-MEG2、SHP-1和SHP-2)的抑制作用,结果显示这些配合物强烈抑制PTP1B的活性,其IC_(50)值在0.15~0.28μmol·L~(-1)范围内,但对PTP-MEG2和SHP-1抑制较弱,几乎不抑制SHP-2,而配合物1、3、5对与PTP1B高度同源的TCPTP的抑制明显强于2和4,因而2和4对PTP1B表现较强的选择性,对PTP1B抑制活性是TCPTP的7~12倍、PTP-MEG2的10~15倍、SHP-1的20~40倍,大约是SHP-2的1 000倍,表明配合物的结构影响其对PTP1B的选择性。酶促动力学实验显示2和4对高度同源的PTP1B和TCPTP抑制类型不同,对PTP1B的抑制为竞争型,而对TCPTP的抑制为非竞争型,推测其选择性可能与其抑制方式有关。荧光滴定表明2和4与PTP1B和TCPTP发生了1∶1结合作用。结合常数分别为1.12×10~6、5.47×10~5、1.19×10~6和4.95×10~5 L·mol~(-1),表明它们与PTP1B的结合能力强于TCPTP,与它们对这两种酶的抑制能力一致。     

双（α－呋喃甲酸）氧钒的合成和抗糖尿病活性研究

设计和合成了一种新型的有机羧酸氧钒配合物双（α－呋喃甲酸）氧钒。运用 元素分析、红外光谱、紫外光谱、质谱和核磁共振氢谱对配合物的结构进行了初步 确证。在实验性动物模型上研究了这个配合物的初步毒性和降血糖作用。结果表明 ：双（α－呋喃甲酸）氧钒具有活性高，安全性好的优点，对糖尿病的治疗显示出 潜在的开发应用前景。     

含咔唑/苯并咪唑环的2,5-二取代-1,3,4-噻二唑酰胺衍生物的合成及对PTP1B/TCPTP抑制活性的评价

合成了一系列新型含咔唑/苯并咪唑环的2,5-二取代-1,3,4-噻二唑酰胺衍生物.利用IR, ~1HNMR, ~(13)CNMR和元素分析对其进行了结构表征.评价了目标化合物对蛋白酪氨酸磷酸酶1B(PTP1B)和T细胞蛋白酪氨酸磷酸酶(TCPTP)的抑制活性,讨论了结构与活性的关系.实验结果显示,绝大多数化合物对PTP1B的抑制活性超过高度同源的TCPTP的抑制活性,其中2-(9-咔唑基亚甲基)-5-(3-氯苯甲酰氨基)-1,3,4-噻二唑(5c)对PTP1B的抑制活性最高[IC_(50)=(2.43±0.43)mg/mL], 2-(9-咔唑基亚甲基)-5-(4-甲基苯甲酰氨基)-1,3,4-噻二唑(5b)和化合物5c对PTP1B的抑制活性均高于阳性对照药物齐墩果酸.对目标化合物5c进行分子对接研究和密度泛函理论(DFT)计算.分子对接结果表明,5c与PTP1B酶通过形成氢键、疏水和p-p等相互作用形成稳定的复合物.     

新型1-(1,3,5-三嗪-6-基)-3-甲基-4-(5-苯基-1,3,4-噁二唑-2-基)吡唑的合成及活性评价

设计合成了18个以吡唑桥连1,3,4-噁二唑和1,3,5-三嗪的新型多杂环分子[7A(a~f),7B(a~f)和7C(a~f)];通过红外光谱(IR)、核磁共振波谱(NMR)和高分辨质谱(HRMS)等对目标分子进行了结构表征;评价了目标分子对蛋白酪氨酸磷酸酯酶1B(PTP1B)和细胞分裂周期25磷酸酯酶B(Cdc25B)的抑制活性.结果表明,所有目标分子对PTP1B和Cdc25B均有较好的抑制活性,其中,9个目标分子表现出优异的PTP1B和Cdc25B抑制效果,IC50值低于齐墩果酸(PTP1B抑制活性测试参照物)和正钒酸钠(Cdc25B抑制活性测试阳性参照物),有望成为潜在的PTP1B和Cdc25B抑制剂.     

水杨醛缩芳胺席夫碱铜(Ⅱ)配合物抑制蛋白酪氨酸磷酸酶活性研究

为了探讨席夫碱配体上取代基变化对其配合物抑制蛋白酪氨酸磷酸酶(PTPs)活性的影响,合成表征了水杨醛缩芳胺席夫碱铜(Ⅱ)配合物[Cu(X-pimp)₂](X=Cl,Br和Acetyl),用紫外光谱滴定和pH电位滴定研究了[Cu(Cl-pimp)₂]的溶液结构,并测定了3个配合物抑制4种PTPs活性的IC₅₀值。结果表明它们都能够有效抑制PTP1B和TCPTP(0.20μmol·L^-1< IC₅₀< 0.31μmol·L^-1),但对SHP-1的抑制较弱且对SHP-2几乎无抑制作用。分析并与文献结果比较发现,席夫碱配体上苯胺对位取代基类型的改变不会显著影响其抑制作用,但取代基位置的改变可能会影响其选择性。稳态动力学研究表明[Cu(Cl-pimp)₂]能够非竞争性抑制PTP1B活性,而荧光光谱实验表明二者形成了键合常数为9.3×10⁶L·mol^-1的1:1复合物。我们推测,配合物可能结合在PTP1B非活性区域,间接导致活性中心结构变化,从而抑制其活性。     

新型含咔唑环芳氨基乙酰腙衍生物的合成及其蛋白酪氨酸磷酸酶1B(PTP1B)抑制活性评价

为寻找新型蛋白酪氨酸磷酸酶1B (PTP1B)抑制剂,设计并合成了一系列新型含咔唑环芳氨基乙酰腙衍生物.其结构和构型用IR、~1H NMR、~(13)C NMR和2D NMR(包括~1H-~1H COSY、~1H-~(13)C HMBC和NOESY)谱及元素分析进行了确证.通过对PTP1B抑制活性的测试发现,目标化合物对PTP1B有较强的抑制作用,且大多数化合物的IC_(50)值低于阳性对照药物齐墩果酸,其中N'-(9-辛基咔唑-3-亚甲基)-2-(4-硝基苯氨基)乙酰肼(3t)活性最高,IC_(50)=(2.78±0.04)μmol/L.利用分子对接研究了化合物3t与PTP1B酶的结合情况.     

新型含咔唑环酰腙衍生物的合成及Cdc25B/PTP1B抑制活性评价

以咔唑和4-氰基氯化苄为初始原料,经多步反应合成出了一系列新型含咔唑基团的酰腙衍生物6,并利用IR、1H NMR、13CNMR和元素分析对其进行了结构表征.对目标化合物进行了Cdc25B/PTP1B抑制活性评价,结果显示,目标化合物6对Cdc25B/PTP1B均具有较高的抑制活性,其中4-[(咔唑-9-基)甲基]-N'-(2-羟基-1-萘亚甲基)苯甲酰肼(6g)对Cdc25B和PTP1B的抑制活性最高, IC50值分别为(2.16±0.38)和(1.06±0.23)?g/mL.对化合物6g进行分子对接的研究结果表明, 6g能与Cdc25B/PTP1B酶形成稳定的复合物,形成氢键和疏水等相互作用.     

Oxidovanadium(IV) Schiff base complex derived from vitamin B6: synthesis, characterization, and insulin enhancing properties

A new Schiff base, [H(4)pydmedpt](2+)·2Cl(-), derived from one of the forms of vitamin B(6) has been synthesized by condensation of pyridoxal hydrochloride with N,N-bis[3-aminopropyl]-methylamine (medpt) and characterized by analytical and spectroscopic methods. The molecular structure is calculated by density functional theory (DFT) procedures, and the donor properties of each individual donor atom are evaluated by calculation of the Fukui function. One pot reaction of pyridoxal and medpt with vanadyl acetylacetonate yields the brown complex [V(IV)O(H(2)pydmedpt)](2+)·2Cl(-)1, which upon recrystallization from water crystallizes as [V(IV)O(pydmedpt)]·5H(2)O 2. The compounds are characterized by analytical and spectroscopic methods, 2 being also characterized by single crystal X-ray diffraction. It displays a slightly distorted octahedral geometry around the vanadium atom involving the coordination of N(amine), two N(imine), and O(phenolato) donors of the ligand. One of the phenolato oxygen donors is positioned trans to the terminal O-oxido atom with relatively short V-O(phenolate) {2.041(3) ?} and long V-O(oxido) {1.625(4) ?} bond distances when compared to other known compounds. The two different pK(a) values (6.0 and 7.9) obtained for 1 are due to protonation of the pyridine ring nitrogen atoms having different basic characters, this being also substantiated by theoretical calculation of the proton affinity of the O- and N- atoms of the molecule. The spin Hamiltonian parameters are obtained from the electron paramagnetic resonance (EPR) spectra, but the A(z) value (ca. 155 × 10(-4) cm(-1)) is lower than expected by applying the additivity rule for the present set of equatorial donor atoms (ca. 162-163 × 10(-4) cm(-1)), this being attributed to the strong trans V-O(phenolate) bond. The UV-vis transitions and EPR spectral parameters are calculated by DFT procedures, and both the calculated electronic transitions and the hyperfine coupling constants agree well with those experimentally observed. The inhibitory effect of 1 on FFA release and % glucose uptake determined with isolated rat adipocyte cells gave IC(50) and EC(50) values lower than for V(IV)OSO(4) and of the same order of magnitude of other reported insulin enhancing vanadium compounds.     

Synthesis and evaluation of oxovanadium(iv) complexes of Schiff-base condensates from 5-substituted-2-hydroxybenzaldehyde and 2-substituted-benzenamine as selective inhibitors of protein tyrosine phosphatase 1B

Five oxovanadium(iv) complexes, which were divided into two groups, [V(IV)O(bhbb, nhbb)(H(2)O)(2)] (tridentate ligands: H(2)bhbb = 2-(5-bromo-2-hydroxylbenzylideneamino)benzoic acid, ; H(2)nhbb = 2-(5-nitro-2-hydroxylbenzylideneamino)benzoic acid, ) and [V(IV)O(cpmp, bpmp, npmp)(2)] (bidentate ligands: Hcpmp = 4-chloro-2-((phenylimino)methyl)phenol, ; Hbpmp = 4-bromo-2-((phenylimino)methyl)phenol, ; Hnpmp = 4-nitro-2-((phenylimino)methyl) phenol, ) have been prepared and characterized by elemental analysis, infrared, UV-visible and electrospray ionization mass spectrometry. The coordination in [V(IV)O(bhbb)(H(2)O)(2)] () was confirmed by X-ray crystal structure analysis. The oxidation state of V(iv) with d(1) configuration in was confirmed by EPR. The speciation of VO/H(2)bhbb in methanol-aqueous solution was investigated by potentiometric pH titrations. The result indicated that the main species were [V(IV)O(bhbb)(OH)](-) and [V(IV)O(bhbb)(OH)(2)](2-) at the pH range 7.0-7.4. The structure-activity relationship of the vanadium complexes in inhibiting protein tyrosine phosphatases (protein tyrosine phosphatase 1B, PTP1B; T-cell protein tyrosine phosphatase, TCPTP; megakaryocyte protein-tyrosine phosphatase, PTP-MEG2; Src homology phosphatase 1, SHP-1 and Src homology phosphatase 2, SHP-2) was investigated. The oxovanadium(iv) complexes were potent inhibitors of PTP1B, TCPTP, PTP-MEG2, SHP-1 and SHP-2, but exhibited different inhibitory abilities over different PTPs. Complexes and displayed better selectivity to PTP1B over the other four PTPs. Kinetic data showed that complex inhibited PTP1B, TCPTP and SHP-1 with a noncompetitive inhibition mode, but a classical competitive inhibition mode for PTP-MEG2 and SHP-2. The results demonstrated that both the structures of vanadium complexes and the conformations of PTPs influenced PTP inhibition activity. The proper modification of the organic ligand moieties may result in screening potent and selective vanadium-based PTP1B inhibitors.     

3,6-二取代三唑并噻二唑衍生物的合成及其对细胞分裂周期25B磷酸酶和蛋白酪氨酸磷酸酶1B抑制活性评价

合成出了一系列含苯并咪唑/芳氧甲基骨架的3,6-二取代三唑并噻二唑衍生物3a~3l,其结构经傅里叶变换红外光谱仪(FT-IR)、核磁共振波谱仪(NMR)和元素分析得以确认。 评价了它们对细胞分裂周期25B磷酸酶(Cdc25B)/蛋白酪氨酸磷酸酶1B(PTP1B)的抑制活性,讨论了构效关系。 生物活性测试结果显示,化合物3a对Cdc25B和PTP1B的抑制活性最高,其半数抑制浓度(IC₅₀)值分别为(0.46±0.02) μg/mL和(1.77±0.40) μg/mL。 所得研究结果为开发新型Cdc25B/PTP1B抑制剂提供了参考依据。     

5-Alkylpyrrole-2-carboxaldehyde derivatives from the Chinese sponge Mycale lissochela and their PTP1B inhibitory activities

Two new 5-alkylpyrrole-2-carboxaldehyde derivatives,mycalenitrile-15(1) and mycalenitrile-16(2),along with five known related ones(3-7),were isolated from the South China Sea sponge Mycale lissochela.The structures of the new compounds were elucidated on the basis of extensive spectroscopic analysis and by comparison of their NMR data with those reported in the literature.In bioassay,compounds 1 and 7 exhibited significant PTPIB(Protein-tyrosine phosphatase 1B,a recognized target for diabetes and obesity) inhibitory activities with IC_(50) values of 8.6 and 3.1 μmoI/L,respectively.A preliminary SAR analysis of the isolated compounds with their PTP1 B inhibitory effects was described.     

1,3,4-(口恶)二唑硫醚酰胺为核心骨架的新型多杂环分子的合成及对Cdc25B与PTP1B的抑制活性

首先利用含有三嗪的芳香酰肼(3)构筑了1,3,4-噁二唑衍生物(5), 然后将化合物5与含有1,3,4-噻二唑的衍生物(6)拼合合成了18个目标分子. 利用红外光谱(IR)、 核磁共振波谱(NMR)和高分辨质谱(HRMS)等技术对其结构进行了表征. 考察了目标分子对细胞分裂周期25磷酸酯酶B(Cdc25B)和蛋白酪氨酸磷酸酯酶1B(PTP1B)的抑制活性. 结果表明, 有8个目标分子的抑制活性优于其阳性对照物, 有望成为潜在的Cdc25B抑制剂; 有12个目标分子的抑制活性优于其对照物, 有望成为潜在的PTP1B抑制剂.     

Gas-phase infrared photodissociation spectroscopy of tetravanadiumoxo and oxo-methoxo cluster anions.

The infrared spectra of the binary vanadium oxide cluster anions V(4)O(9)(-) and V(4)O(10)(-) and of the related methoxo clusters V(4)O(9)(OCH(3))(-) and V(4)O(8)(OCH(3))(2)(-) are recorded in the gas phase by photodissociation of the mass-selected ions using an infrared laser. For the oxide clusters V(4)O(9)(-) and V(4)O(10)(-), the bands of the terminal vanadyl oxygen atoms, nu(V-O(t)), and of the bridging oxygen atoms, nu(V-O(b)-V), are identified clearly. The clusters in which one or two of the oxo groups are replaced by methoxo ligands show additional absorptions which are assigned to the C-O stretch, nu(C-O). Density functional calculations are used as a complement for the experimental studies and the interpretation of the infrared spectra. The results depend in an unusual way on the functional employed (BLYP versus B3LYP), which is due to the presence of both V-O(CH(3)) single and V=O double bonds as terminal bonds and to the strong multireference character of the latter.     

基于咔唑的新型碳酰腙衍生物的合成及蛋白酪氨酸磷酸酶1B(PTP1B)抑制活性评价

合成出了一系列新型基于咔唑的单-/双-碳酰腙衍生物3和4.利用1H NMR、13C NMR、IR和元素分析对其进行了结构表征.评价了目标化合物对蛋白酪氨酸磷酸酶1B(PTP1B)的抑制活性,讨论了结构与活性的关系.实验结果显示,大部分化合物对PTP1B具有良好的抑制活性,其中1,5-双[(9-丁基-3-咔唑基)亚甲基]碳酰腙(4c)的抑制活性最高,IC50=(4.81±0.41)mmol/L,且活性高于对照药物齐墩果酸.对目标化合物1-[(9-庚基-3-咔唑基)亚甲基]碳酰腙(3f)和4c进行分子对接研究和密度泛函理论(DFT)计算.分子对接结果表明,化合物3f和4c结合到PTP1B酶由螺旋α3和α6形成的活性位点,与PTP1B酶通过氢键、极性、疏水和p-p等相互作用形成了稳定的复合物.     

基于咔唑的单-/双-硫代碳酰腙衍生物的合成及Cdc25B/PTP1B抑制活性评价

合成了一系列新型的基于咔唑的单-/双-硫代碳酰腙衍生物.利用IR、1H NMR、13C NMR和元素分析对其进行了结构表征.评价了目标化合物对Cdc25B和PTP1B的抑制活性,讨论了其结构与活性的关系.实验结果显示,大部分目标化合物对Cdc25B和PTP1B表现出良好的抑制活性.其中,1,5-双[(9-戊基-3-咔唑基)亚甲基]硫代碳酰腙(4d)对Cdc25B的抑制活性最高,IC50为(0.23±0.02)μg/m L.1,5-双[(9-乙基-3-咔唑基)亚甲基]硫代碳酰腙(4a)对PTP1B的抑制活性最高, IC50为(1.00±0.16)μg/m L.对目标化合物4a和4d进行分子对接研究和密度泛函理论(DFT)计算,结果表明,目标化合物4d和4a分别进入到了Cdc25B和PTP1B酶的活性位点区域,有活性作用的主要是硫代碳酰腙和咔唑基团.     

Bioactive rearranged limonoids from the Chinese mangrove Xylocarpus granatum Koenig

Two new pyridine-containing limonoids, xylogranatopyridines A and B (1 and 2) and their formal precursor, prexylogranatopyridine (3) were isolated from the twigs and leaves of the Chinese mangrove, Xylocarpus granatum. Xylogranatopyridine B (2) possesses an unprecedented rearranged B-ring together with a seco-ring A, supporting the biogenetic connection of 1–2 with 3. The chemical structures were elucidated by means of detailed spectroscopic analysis and X-ray single-crystal diffraction. The absolute configurations were assigned using electronic solid-state circular dichroism (ECD) supported by time-dependent density functional theory (TDDFT) ECD calculations and X-ray analysis. Xylogranatopyridine A (1) exhibited a significant inhibitory activity against protein tyrosine phosphatase 1B (PTP1B) with an IC₅₀ value of 22.9 μM. This is the first report of PTP1B inhibitory activity of limonoids.